Tuesday 18 June 2019 ,
Tuesday 18 June 2019 ,
Latest News
  • Nuke project graft accused a BNP man: PM
  • Last phase UZ polls Tuesday
  • Ex-Sonagazi OC Moazzem denied bail, sent to jail
  • Probe report on Biman pilot’s travel without passport submitted
  • 2 female pilots bring pride for Bangladesh in Congo
  • No liquidity crisis in banking sector: PM
25 March, 2019 00:00 00 AM
Print

FDA approves Trazimera (trastuzumab-qyyp) for the treatment of Breast Cancer, Gastric Cancer

drugs.com
FDA approves Trazimera (trastuzumab-qyyp) for the treatment of Breast Cancer, Gastric Cancer

Pfizer Inc. recently announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab), for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

“This is an important milestone in the U.S. which both adds to our growing portfolio of oncology treatments and has the potential to improve access to cancer care,” said Andy Schmeltz, Global President, Pfizer Oncology. “We are proud to be able to offer treatment options that can help address the diverse needs of patients.”

The FDA approval was based on review of a comprehensive data package, which demonstrated a high degree of similarity between Trazimera and the originator product. This includes results from the REFLECTIONS B327-02 clinical comparative study that was recently published in the British Journal of Cancer, which showed clinical equivalence, finding a high degree of similarity and no clinically meaningful differences between Trazimera and the originator product in patients with first line HER2 overexpressing metastatic breast cancer.

“Approximately 15-30% of breast cancers and 10-30% of gastric cancers are HER2-positive, which is associated with aggressive disease and poor prognoses for patients,” said Dr. Mark Pegram, associate director for clinical research at the Stanford Comprehensive Cancer Institute, and director of the Breast Oncology Program at the Stanford Women’s Cancer Center.4 “With the availability of biosimilars like Trazimera in the U.S., oncologists will have additional treatment options to choose from, which may help provide patients with greater access to the medicines they need.”

Pfizer has a robust portfolio of potential biosimilar candidates in mid- to late-stage development. Trazimera is Pfizer’s first oncology monoclonal antibody (mAb) biosimilar and Pfizer’s fifth biosimilar to be approved by the FDA.

About Trazimera (trastuzumab-qyyp)

Trazimera is a monoclonal antibody (mAb) biosimilar of the originator biologic medicine, Herceptin, which targets HER2, a protein found on the surface of some cancer cells which can stimulate the cells to divide and grow. Trazimera locks on to the HER2 protein and blocks the receptors, stopping cell division and growth.

As part of the REFLECTIONS clinical trial program, Trazimera has been studied in nearly 500 patients and across more than 20 countries to date.

Possible serious side effects with Trazimera (trastuzumab–qyyp)

Not all people have serious side effects, but side effects with Trazimera therapy are common.

Although some people may have a life-threatening side effect, most do not.

Your doctor will stop treatment if any serious side effects occur.

Trazimera is not for everyone. Be sure to contact your doctor if you are experiencing any of the following:

Heart problems

These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both trastuzumab and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with Trazimera.

Infusion reactions, including:

Fever and chills

Feeling sick to your stomach (nausea)

Throwing up (vomiting)

Pain (in some cases at tumor sites)

Headache

Dizziness

Shortness of breath

These signs usually happen within 24 hours after receiving Trazimera.

Be sure to contact your doctor if you:

Are a woman who could become pregnant, or may be pregnant

Trazimera may result in the death of an unborn baby or birth defects. Contraception should be used while receiving Trazimera and after your last dose of Trazimera.

Have any signs of severe lung  problems, including:

Severe shortness of breath

Fluid in or around the lungs

Weakening of the valve between the heart and the lungs

Not enough oxygen in the body

Swelling of the lungs

Scarring of the lungs

Your doctor may check for signs of severe lung problems when he or she examines you.

Have low white blood cell counts

Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving trastuzumab plus chemotherapy than in patients receiving chemotherapy alone.

Your doctor may check for signs of low white blood cell counts when he or she examines you.

Side Effects Seen Most Often With trastuzumab

Some patients receiving trastuzumab for breast cancer had the following side effects:

Fever

Feeling sick to your stomach (nausea)

Throwing up (vomiting)

Infusion reactions

Diarrhea

Infections

Increased cough

Headache

Feeling tired

Shortness of breath

Rash

Low white and red blood cell counts

Muscle pain

Some patients receiving trastuzumab for metastatic stomach cancer had the following side effects:

Low white blood cell counts

Feeling tired

Low red blood cell counts

Swelling of the mouth lining

Weight loss

Upper respiratory tract infections

Fever

Low platelet counts

Swelling of the mucous membranes

Swelling of the nose and throat

Change in taste

You should contact your doctor immediately if you have any of the side effects listed above.

Comments

Poll
Today's Question »
State minister for power Nasrul Hamid yesterday said everyone to have access to electricity by June. Do you think the feat achievable by the timeframe?
 Yes
 No
 No Comment
Yes 49.7%
No 46.2%
No Comment 4.1%
Most Viewed
Digital Edition
Archive
SunMonTueWedThuFri Sat
01
02030405060708
09101112131415
16171819202122
23242526272829
30

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting